PledPharma Seeks Partner For Lead Therapy
Executive Summary
Jacques Näsström, CEO of Pled Pharma, chats with Sten Stovall, senior editor at Pharma Insights, about the company’s current hunt for licensing partners for lead product PledOx (calmangafodipir), which is being developed as a preventative therapy against nerve damage associated with cytotoxic therapy in colorectal cancer patients.
You may also be interested in...
PledPharma moves forward with neuropathy drug; seeks partner
PledPharma is seeking a partner for its colorectal cancer therapy PledOx, on the back of mostly positive results for the drug in a Phase IIb study.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.